Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Vaishnavi Putcha
Institutions:
Georgia Institute of Technology,
Emory University,
The Wallace H. Coulter Department of Biomedical Engineering
Observed institutions:
Georgia Institute of Technology,
Emory University,
The Wallace H. Coulter Department of Biomedical Engineering
ORCID:
0009-0008-0970-4457
Observed ORCID:
0009-0008-0970-4457
OpenAlex ID:
A5130392473
AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial
2026
·
Sebastian Medina
, Naoto Tokuyama
, et al.
·
Clinical Cancer Research
·
3
An AI-based pathology classifier to predict benefit from enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC) from ENZAMET (ANZUP 1304).
2026
·
Sebastian R. Medina
, Naoto Tokuyama
, et al.
·
Journal of Clinical Oncology
·
1
Supplementary Figure S1 from AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial
2026
·
Sebastian Medina
, Naoto Tokuyama
, et al.
Supplementary Table S4 from AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial
2026
·
Sebastian Medina
, Naoto Tokuyama
, et al.
Supplementary Figure S3 from AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial
2026
·
Sebastian Medina
, Naoto Tokuyama
, et al.
Supplementary Figure S10 from AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial
2026
·
Sebastian Medina
, Naoto Tokuyama
, et al.
Supplementary Table S3 from AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial
2026
·
Sebastian Medina
, Naoto Tokuyama
, et al.
Supplementary Figure S5 from AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial
2026
·
Sebastian Medina
, Naoto Tokuyama
, et al.
Supplementary Results 1 from AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial
2026
·
Sebastian Medina
, Naoto Tokuyama
, et al.
Supplementary Table S1 from AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial
2026
·
Sebastian Medina
, Naoto Tokuyama
, et al.
Supplementary Table S2 from AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial
2026
·
Sebastian Medina
, Naoto Tokuyama
, et al.
Data from AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial
2026
·
Sebastian Medina
, Naoto Tokuyama
, et al.
Supplementary Figure S7 from AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial
2026
·
Sebastian Medina
, Naoto Tokuyama
, et al.
Supplementary Figure S6 from AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial
2026
·
Sebastian Medina
, Naoto Tokuyama
, et al.
Supplementary Figure S2 from AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial
2026
·
Sebastian Medina
, Naoto Tokuyama
, et al.
Supplementary Figure S4 from AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial
2026
·
Sebastian Medina
, Naoto Tokuyama
, et al.
Supplementary Figure S9 from AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial
2026
·
Sebastian Medina
, Naoto Tokuyama
, et al.
Supplementary Figure S8 from AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial
2026
·
Sebastian Medina
, Naoto Tokuyama
, et al.
Supplementary Methods 1 from AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial
2026
·
Sebastian Medina
, Naoto Tokuyama
, et al.
1120 Prognostic Utility of Tumor Multinucleation Density in Oral Cavity Squamous Cell Carcinoma Using AI-Driven Digital Pathology
2026
·
Sandeep Manandhar
, Vaishnavi Putcha
, et al.
·
Laboratory Investigation
834 Computational Pathology Captures Nuclear Morphology Alterations Following Neoadjuvant Chemohormonal Therapy (NCHT) in High Risk Localized Prostate Cancer
2026
·
Sebastian Medina
, Puchangxin Li
, et al.
·
Laboratory Investigation
Show more works
View as search
Works count:
21
Citation count:
4
H-index:
1
I10-index:
Year
Topic
Type